Pharmaceutical Investing Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma
Pharmaceutical Investing Reata Pharmaceuticals Announces First Quarter 2018 Financial Results and an Update on Development Programs
Pharmaceutical Investing OncoMed Announces First Quarter 2018 Financial Results and Operational Highlights
Pharmaceutical Investing miRagen Therapeutics Announces New Interim Data From Phase 1 Clinical Trial of Cobomarsen in Mycosis Fungoides
Pharmaceutical Investing Xenon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
Pharmaceutical Investing Nabriva Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights
Pharmaceutical Investing Cellular Biomedicine Group Reports First Quarter 2018 Financial Results and Highlights Operational Progress
Pharmaceutical Investing Verona Pharma plc Operational Update and Financial Results for the First Quarter Ended March 31, 2018
Eloxx Pharmaceuticals Announces FDA Grant of Orphan-Drug Designation for Investigational Drug ELX-02 for Treatment of Cystinosis
Pharmaceutical Investing Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006
Pharmaceutical Investing Axsome Therapeutics Announces Positive Outcome of Interim Analysis of STRIDE-1 Phase 3 Trial of AXS-05
